Standard Chartered Targets Higher Profitability With Major Workforce Cuts 
Google, Blackstone Launch $5B AI Cloud Venture to Challenge Nvidia and CoreWeave 
DOJ May Drop Gautam Adani Fraud Charges Amid $10 Billion U.S. Investment Plan 
Amazon Faces Class-Action Lawsuit Over Trump Tariff Price Hikes 
SpaceX Shareholders Approve 5-for-1 Stock Split Ahead of Potential IPO 
Samsung Strike Talks Resume as South Korea Weighs Emergency Action 
Standard Chartered Appoints Manus Costello as New CFO Amid Leadership Reshuffle 
Honda Shares Jump as Automaker Forecasts Profit Recovery Despite Historic Loss 
FTC Antitrust Probe Targets Arm Holdings Over Chip Licensing Practices 
Thyssenkrupp to Shut Down Indiana Automotive Plant by March 2026 
Asia-Pacific Banks Brace for Rising Credit Risks Amid Iran Conflict 
OpenAI Wins Elon Musk Lawsuit as Jury Rejects Claims Over AI Mission 
YouTube and Snap Settle School District Mental Health Lawsuit Ahead of Major Social Media Trial 
Anthropic to Brief Financial Stability Board on AI-Driven Cyber Risks 
Applied Materials Forecasts Strong Q3 Revenue as AI Chip Demand Accelerates 
GREENSBORO, N.C., Sept. 21, 2016 -- Mucodel Pharma LLC (“Mucodel”) today announced the successful completion of a pilot clinical study involving buccal naloxone (Exonal™), a Mucodel product under development for the reversal of opioid overdose.
Exonal™ employs Mucodel’s Co-Gel platform for oromucosal delivery of pharmaceutically active agents and is particularly suitable for rescue therapeutics requiring rapid absorption.
The pilot pharmacokinetic study compared Exonal™ buccal naloxone with an approved intramuscular injectable naloxone.
The study met its objectives and demonstrated that Exonal™ rapidly delivered the targeted naloxone dose, with comparable Cmax and Tmax to the approved intramuscular injectable reference product.
Founder and CEO, Dr. Madhu Hariharan, stated: “We are pleased with the pilot clinical results for Exonal™ buccal naloxone. The remarkably rapid transit of naloxone through the buccal mucosal barrier for this critical rescue therapy speaks very well for our Co-Gel platform technology.”
Joseph Fuisz, head of business development, stated: “Exonal™ buccal naloxone offers a series of substantial value added features as compared with existing treatment options including improved reliability and ease of administration. Dosing placement can be readily taught and seen.”
Naloxone is a Food and Drug Administration (FDA) approved agent that treats the effects of opioid overdose caused by the use or misuse of prescription and illicit opioids. US deaths from opioid overdose currently exceed 8 per 100,000, are increasing further and are on track to eclipse automobile fatalities (10.25 per 100,000). The majority of deaths occur at home.
Currently, there is no approved naloxone rescue product with an oromucusol route of administration. FDA approved formulations of rescue naloxone include injectable products and a nasal spray.
About Mucodel Pharma:
The mission of Mucodel is to develop improved rescue therapies that are oromucosally administered. Mucodel’s proprietary Co-Gel technology allows for oromucosal administration of existing drugs that would not otherwise be amenable to oromucosal delivery. Mucodel’s Co-Gel platform enables more convenient products and offers tangible therapeutic benefits to patients.
Mucodel is a private company based in Greensboro, North Carolina. www.mucodel.com
Media Contact: Madhu Hariharan [email protected] Business Development Contact: Joseph Fuisz [email protected]
